France's Novacyt H1 revenue rises on SCD acquisition

Novacyt SA

28/07/2026 07:16

Overview
France molecular diagnostics firm's H1 2026 revenue rose 18% yr/yr to £11.6 mln
Southern Cross Diagnostics contributed £1.8 mln revenue post-acquisition in March
Company expects up to £4.0 mln annualised cost savings from ongoing restructuring

Outlook
Company expects restructuring to deliver up to £4.0 mln annualised cost savings
Novacyt expects IVDR accreditation for DPYD kit in coming months

Result Drivers
SEGMENT GROWTH - Instrumentation segment revenue rose about 30% yr/yr, reflecting market adoption of LightBench Discover platform
CLINICAL DEMAND - Clinical segment grew more than 20% yr/yr, driven by demand for NIPT technology and inclusion of SCD sales
REGIONAL PERFORMANCE - Americas and Asia-Pacific saw strong revenue growth, with Americas up over 30% and Asia-Pacific up about 22%, supported by instrument and reproductive health demand

Company press release: ID:nRSb9972Na

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
GBP 11.60 mln
 

Reuters Recommended Reads
July 27 - AstraZeneca Q2 revenue rises 6% on demand for its cancer therapies
July 27 - OPKO Health Q2 loss narrows on higher IP revenue, lower costs
July 27 - UK's Science Group preliminary H1 core revenue falls; expects buyback to exceed £20 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)